Novan Reshapes Executive Management Team

Former Quintiles Executive Paula Brown Stafford Joins Novan as Chief Development Officer

Stanley Hollenbach Promoted to Senior Vice President of Research and Development

William L. Hodges Appointed as Interim Chief Financial Officer on Departure of Richard Peterson

Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced adjustments to the executive management team that aim to strengthen the Company’s clinical operations infrastructure and streamline the research and development group as the Company prepares to execute multiple late-stage development programs. Paula Brown Stafford has been appointed to the newly created position of Chief Development Officer, in which she will be responsible for the tactical execution of clinical trials and the establishment of statistics and data management functions at the Company. Ms. Stafford has more than 30 years of experience in the biopharmaceutical services industry, including roles in project management, biostatistics, global clinical operations and executive leadership. She will team with Dr. Joyce Rico, Chief Medical Officer, as Novan prepares for upcoming interactions with the U.S. Food and Drug Administration, or FDA, including the planned pre-submission meeting regarding a potential new drug application for SB204.